ALNY News and Press, Alnylam Pharmaceuticals Inc.

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that it will report financial results for the second quarter ending June 30, 2024 on Thursday, August 1, 2024, before the U.S. financial markets open. Management will provide an update on th...

2024-07-17 16:47:26 ET Summary VIR develops medicines for infectious and viral diseases using proprietary platforms for monoclonal antibodies and T cell-based Viral Vectors. Positive Phase 2 trial results for chronic hepatitis delta highlight the company's potential to address unm...

2024-07-11 06:30:00 ET InvestorPlace - Stock Market News, Stock Advice & Trading Tips Could Alnylam Pharmaceuticals (NASDAQ: ALNY ) become a household name in 2024? At the very least, the company should be well known in the medical community. If you like to wager...

2024-07-09 15:00:45 ET More on BioMarin Pharmaceutical, Legend Biotech, etc. Silence Therapeutics: PV Data For Consideration After ASCVD Treatment Results BioMarin: Short-Term Headwinds But Long-Term Opportunities Remain Legend Biotech's Carvykti Faces Stiff Challeng...

2024-07-09 07:00:00 ET Summary Biotech indexes lagged broader market indexes in the first half of 2024, and trade at the same level as in early 2022. Biotech valuations are closely tied to the Fed's interest rate policy and are highly correlated to the 10-year yield. Inflation...

2024-06-30 20:30:56 ET Rounding out the top five were Moderna ( NASDAQ: MRNA ) and Novo Nordisk ( NVO ) with gains of, respectively, ~12.5% and ~11.9% .... Read the full article on Seeking Alpha For further details see: Alnylam, Lilly, AstraZeneca among best ...

2024-06-29 16:24:00 ET Stock Traders Daily has produced this trading report using a proprietary method.  This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...

2024-06-27 10:00:05 ET Luca Issi from RBC Capital issued a price target of $265.00 for ALNY on 2024-06-27 08:30:00. The adjusted price target was set to $265.00. At the time of the announcement, ALNY was trading at $245.17. The overall price target consensus is at $225.4...

2024-06-27 08:24:25 ET Summary Agilent's may be an underappreciated winner with Alnylam's recent clinical success, as manufacturing Amvuttra could generate more than $500M in revenue in the coming 5-7 years that isn't in models. Sharp cutbacks in capex spending across academic lab...

A look at the top 10 most actives in the United States Faraday Future Intelligent Electric Inc. (FFIE) rose 73.0% to $0.4585 on volume of 640,087,036 shares Ocean Power Technologies Inc. (OPTT) rose 34.9% to $0.1812 on volume of 396,326,565 shares NVIDIA Corporation (NVDA) rose 0.2% to $1...